

Sanofi-Aventis: PharmaVitae Profile 2007

Published: 2007-DEC-19

Pages: 155

Format: PDF & SlidePack

Price: 5700 USD

Description

Introduction

This analysis examines the historical and forecast performance for Sanofi-Aventis in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark Sanofi-Aventis's performance against key rivals in the ethical pharmaceutical sector See how, as 2012 approaches, the company's mature core product portfolio will face an increased risk of generic exposure, hampering sales growth Evaluate the prospects of the Sanofi-Aventis's late-stage pipeline, which must fulfill its potential if growth is to be sustained in the long term.

Table of Contents

CHAPTER 1 EXECUTIVE SUMMARY 2

Key findings 2

Historical and forecast ethical sales performance 3

Therapeutic strategy 5

Launch and expiry outlook 10

Externalization, geographic and molecule type strategies 13

Externalization strategy 14

Geographic strategy 15

Molecule type strategy 15

SWOT analysis 17

Strengths 17

Weaknesses 20

Opportunities 21

Threats 21

CHAPTER 2 CORPORATE HISTORY 26

Key findings 26

Background 27

M&A history 28

Sanofi-Synthelabo 28

Aventis 28

M&A strategy 29

Increase US market presence 30

Therapy area diversification 30

Patent risk dilution 30

Creation of thrombotic powerhouse 31

Current corporate structure 31

CHAPTER 3 HISTORICAL PERFORMANCE 33

Key findings 33

Introduction 34

Revenue and growth rate analysis, 2001-06 34

Revenue and growth rate vs. peer set 35

Product analysis, 2001-06 37

Growth drivers 37

Eloxatine 37

BioMarket Group - A Global Online Aggregator of Life Science Market Research

| |
|---|
| Lantus 38 |
| Plavix 38 |
| Stilnox 39 |
| Lovenox 39 |
| Growth resistors 40 |
| Allegra/Telfast 40 |
| Operating revenue and cost analysis, 2001-06 41 |
| Operating revenue/cost analysis 42 |
| CHAPTER 4 FORECAST PERFORMANCE 44 |
| Key findings 44 |
| Introduction 45 |
| Revenue and growth rate, 2006-12 45 |
| Product analysis, 2006-12 47 |
| Growth drivers 53 |
| Eloxatine 53 |
| Lantus 54 |
| Vaccines franchise 54 |
| Lovenox 54 |
| Eplivanserin 55 |
| Growth resistors 55 |
| Ambien/Stilnox 55 |
| Taxotere 55 |
| Therapy area analysis, 2006-12 57 |
| Oncology 59 |
| Endocrine, metabolic & genetic disorders 60 |
| Cardiovascular & hematology 60 |
| Infectious diseases 60 |
| CNS 61 |
| Therapy area focus 62 |
| Launches and expiries analysis, 2006-12 68 |
| Launch portfolio 69 |
| Core portfolio 71 |
| Expiry portfolio 73 |
| Launch/core/expiry configuration 75 |
| Externalization analysis, 2006-12 80 |
| Geographic analysis, 2006-12 85 |
| Molecule type analysis, 2006-12 89 |
| CHAPTER 5 KEY PRODUCTS AND COMPETITORS 94 |
| Key findings 94 |
| Overview 95 |
| Cardiovascular & hematology 96 |
| Lovenox 96 |
| Overview 96 |
| Sales forecast 97 |
| Newsflow 97 |
| Plavix 104 |
| Overview 104 |
| Sales forecast 105 |
| Newsflow 105 |
| Oncology 108 |
| Eloxatine 108 |
| Overview 108 |
| Sales forecast 109 |
| Newsflow 109 |
| Taxotere 114 |
| Overview 114 |
| Sales forecast 115 |
| Newsflow 115 |
| Gardasil 121 |
| Overview 121 |
| Sales forecast 122 |
| Newsflow 123 |
| Endocrine, metabolic & genetic disorders 128 |
| Lantus 128 |
| Overview 128 |
| Sales forecast 129 |
| Newsflow 129 |
| CNS 132 |
| Ambien/Stilnox 132 |
| Overview 132 |
| Sales forecast 133 |
| Newsflow 133 |
| Eplivanserin 138 |
| Overview 138 |
| Sales forecast 139 |
| Newsflow 139 |

BioMarket Group - A Global Online Aggregator of Life Science Market Research

Infectious diseases 141

Menactra 141

Overview 141

Sales forecast 142

Newsflow 142

CHAPTER 6 APPENDIX 146

IMS vs. company-reported data reconciliation 146

Abbreviations 148

Exchange rates 149

List of Tables

Table 1: Peer set overview 35

Table 2: Operating revenue/cost analysis (\$m), 2001-06 41

Table 3: Operating cost ratio analysis (% of total revenues), 2001-06 42

Table 4: Product portfolio overview, sales (\$m), 2006-12 47

Table 5: Therapy area overview, sales (\$m), 2006-12 57

Table 6: Launch portfolio overview, sales (\$m), 2006-12 69

Table 7: Core portfolio overview, sales (\$m), 2006-12 71

Table 8: Expiry portfolio overview, sales (\$m), 2006-12 73

Table 9: Externally developed portfolio (\$m), 2006-12 80

Table 10: Molecule type overview, sales (\$m), 2006-12 89

Table 11: Key products overview 95

Table 12: Lovenox: overview 96

Table 13: Lovenox: sales forecast (\$m), 2006-12 97

Table 14: Lovenox: news flow 97

Table 15: Plavix: overview 104

Table 16: Plavix: sales forecast (\$m), 2006-12 105

Table 17: Plavix: news flow 105

Table 18: Eloxatin: overview 108

Table 19: Eloxatin: sales forecast (\$m), 2006-12 109

Table 20: Eloxatin: news flow 109

Table 21: Taxotere: overview 114

Table 22: Taxotere: sales forecast (\$m), 2006-12 115

Table 23: Taxotere: news flow 115

Table 24: Gardasil: overview 121

Table 25: Gardasil: sales forecast (\$m), 2006-12 122

Table 26: Gardasil: news flow 123

Table 27: Lantus: overview 128

Table 28: Lantus: sales forecast (\$m), 2006-12 129

Table 29: Lantus: news flow 129

Table 30: Ambien/Stilnox: overview 132

Table 31: Ambien/Stilnox: sales forecast (\$m), 2006-12 133

Table 32: Ambien/Stilnox: news flow 133

Table 33: Eplivanserin: overview 138

Table 34: Eplivanserin: sales forecast (\$m), 2006-12 139

Table 35: Eplivanserin: news flow 139

Table 36: Menactra: overview 141

Table 37: Menactra: sales forecast (\$m), 2006-12 142

Table 38: Menactra: news flow 142

Table 39: Exchange rates, 2006 149

List of Figures

Figure 1: Historical and forecast ethical sales performance (% CAGR), Sanofi-Aventis and Big Pharma peer set 3

Figure 2: Therapeutic focus vs. Big Pharma peer set (%), 2006 6

Figure 3: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), Sanofi-Aventis 10

Figure 4: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set 12

Figure 5: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2006 13

Figure 6: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2012 14

Figure 7: SWOT analysis of Sanofi-Aventis 17

Figure 8: Current corporate structure 32

Figure 9: Revenue & growth rate (ethical sales) (\$m), 2001-06 34

Figure 10: Ethical revenue (\$m) and growth rate (%) vs. peer set, 2001-06 36

Figure 11: Growth drivers/resistor products of historical revenue performance (\$m), 2001-06 37

Figure 12: Operating revenue/cost analysis (\$m), 2001-06 42

Figure 13: Operating cost ratio analysis (% of total revenues), 2001-06 43

Figure 14: Ethical revenue (\$m) and growth rate (%), 2006-12 46

Figure 15: Top five products by sales (\$m), 2006 49

Figure 16: Top five products by sales (\$m), 2012 52

Figure 17: Growth drivers and resistors by product, 2006-12 53

Figure 18: Key strategic products, sales (\$m), 2006-12 56

Figure 19: Ethical sales by therapy area (\$m), 2006-12 58

Figure 20: Growth drivers and resistors by therapy area (\$m), 2006-12 59

Figure 21: Ethical sales by therapy area (%), 2006-12 62

Figure 22: Therapy area focus compared with peer set (% total ethical sales), 2006 65

Figure 23: Therapy area focus compared with peer set (% total ethical sales), 2012 67

Figure 24: Launch schedule, sales (\$m), 2006-12 70

Figure 25: Core products sales growth (\$m), 2006-12 72

Figure 26: Expiry schedule, sales (\$m), 2006-12 74

BioMarket Group - A Global Online Aggregator of Life Science Market Research

Figure 27: Launch, core and expiry, sales (\$m), 2006-12 75
Figure 28: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), Sanofi-Aventis 78
Figure 29: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set 79
Figure 30: Externalization dependency, sales (\$m), 2006-12 81
Figure 31: Growth drivers and resistors, externally vs. internally discovered products, sales (\$m), 2006-12 82
Figure 32: Externalization dependency vs. peer set, % total sales, 2006 83
Figure 33: Externalization dependency vs. peer set, % total sales, 2012 84
Figure 34: Geographical sales breakdown (\$m), 2006-12 85
Figure 35: Growth drivers and resistors by geography, sales (\$m), 2006-12 86
Figure 36: US dependency vs. peer set, % total sales, 2006 87
Figure 37: US dependency vs. peer set, % total sales, 2012 88
Figure 38: Growth drivers and resistors by molecule type, sales (\$m), 2006-12 90
Figure 39: Molecule type sales breakdown (\$m), 2006-12 91
Figure 40: Biologics dependency vs. peer set, % total sales, 2006 92
Figure 41: Biologics dependency vs. peer set, % total sales, 2012 93
Figure 42: IMS vs. company-reported ethical sales discrepancy (\$m), 2006 147
Figure 43: IMS vs. company-reported ethical sales forecast growth rates (%), 2006-12 148

Ordering

Order Online - <http://www.biomarketgroup.com/market-research-report/sanofi-aventis-pharmavitae-profile-2007.html>

Order by Fax - using the form below

Order by Post - print the order form below and send to:

BioMarket Group
Björnnäsvägen 21
11419 STOCKHOLM
SWEDEN

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to +46-8-56849191. If you have any questions please visit

<http://www.biomarketgroup.com/index.php/contacts/>

Order Information

Please verify that the product information is correct:

Product Name: **Sanofi-Aventis: PharmaVitae Profile 2007**

Web Address: <http://www.biomarketgroup.com/market-research-report/sanofi-aventis-pharmavitae-profile-2007.html>

Format: PDF & SlidePack

Price: 5700 USD (Single User License)

Delivery of hard copy or CD-ROM is subject to a Courier charge of 50 USD.

Delivery within Sweden is subject to VAT at 25%.

Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: _____

Name: _____

Email Address:* _____

Job Title: _____

Organization: _____

EU companies must supply: VAT / BTW / MOMS

MWST / IVA / FPA number:

Address: _____

Zip Code: _____

City: _____

State: _____

Country: _____

Phone Number: _____

Fax Number: _____

Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:**
- American Express
 - Master Card
 - Visa

Cardholder Name: _____

Expiry Date (MM/YY): _____

Card Number: _____

CVV Number: _____

- Pay by check:**

Please post the check, accompanied by this form, to:

BioMarket Group
Björnnäsvägen 21
11419 STOCKHOLM
SWEDEN

- Pay by wire transfer:** Please transfer funds to:

Account number: 43521169

Swift code: HANDSESS

IBAN number: SE74 6000 0000 0000 4352 1169

Bank Address: Handelsbanken, Stockholm, Sweden

If you have a Marketing Code please enter it below:

Marketing Code: _____

Please supply purchase order number if needed:

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, Gmail)

Please note that by ordering from BioMarket Group you are agreeing to our Terms and Conditions at

<http://www.biomarketgroup.com/index.php/biomarket-group-full-terms-and-conditions>

Please fax this form to: +46-8-56849191